Vitiligo - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 62 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Vitiligo - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Vitiligo - Pipeline Review, H2 2015', provides an overview of the Vitiligo's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vitiligo, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vitiligo and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vitiligo
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vitiligo and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vitiligo products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vitiligo pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vitiligo
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vitiligo Overview 6
Therapeutics Development 7
Pipeline Products for Vitiligo - Overview 7
Pipeline Products for Vitiligo - Comparative Analysis 8
Vitiligo - Therapeutics under Development by Companies 9
Vitiligo - Therapeutics under Investigation by Universities/Institutes 10
Vitiligo - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Vitiligo - Products under Development by Companies 13
Vitiligo - Products under Investigation by Universities/Institutes 14
Vitiligo - Companies Involved in Therapeutics Development 15
Ache Laboratorios Farmaceuticos S/A 15
Biocon Limited 16
Bristol-Myers Squibb Company 17
Clinuvel Pharmaceuticals Limited 18
Sun Pharma Advanced Research Company Ltd. 19
Vitiligo - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
abatacept - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ACH-24 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
afamelanotide - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Gene Therapy to Activate SOX9 for Vitiligo and Melanoma - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
itolizumab - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SUN-0597 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VLRX-001 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Vitiligo - Recent Pipeline Updates 43
Vitiligo - Dormant Projects 51
Vitiligo - Product Development Milestones 52
Featured News & Press Releases 52
May 05, 2015: Clinuvel announces innovative melanocortin for new indications 52
Mar 20, 2015: SCENESSE vitiligo data presented at world's largest dermatology conference 53
Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology 54
May 06, 2014: Clinuvel's Phase II vitiligo study commences in Singapore 54
Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology 55
Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore 56
Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients 56
Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference 58
Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo 58
Oct 16, 2012: Observations from Clinuvels US vitiligo study published 59
Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 61
Disclaimer 62

List of Tables

Number of Products under Development for Vitiligo, H2 2015 7
Number of Products under Development for Vitiligo - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Vitiligo - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2015 15
Vitiligo - Pipeline by Biocon Limited, H2 2015 16
Vitiligo - Pipeline by Bristol-Myers Squibb Company, H2 2015 17
Vitiligo - Pipeline by Clinuvel Pharmaceuticals Limited, H2 2015 18
Vitiligo - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Vitiligo Therapeutics - Recent Pipeline Updates, H2 2015 43
Vitiligo - Dormant Projects, H2 2015 51